Q3 2022
Released Feb 4, 2022, before the open
10-Q filed Feb 4, 2022, 35 days after period end · 0001764013-22-000031
Q3 2022 · 10-Q
Revenue—
Net Income-$41.39M-$41.39M no prior Q3 2021 on fileN/M vs Q2 2022
EPS Diluted-$0.36-$0.36 no prior Q3 2021 on fileN/M vs Q2 2022
Operating Cash Flowderived-$31,895,000—
Free Cash Flowderived-$31,969,000—
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2018 |
|---|---|---|
| Net Income | -$41.39M | -$8.85M |
| EPS Diluted | -$0.36 | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR